APOB

(redirected from apoB-100)
Also found in: Encyclopedia.

APOB

A gene on chromosome 2p24-p23 that encodes apolipoprotein B, the main apoliprotein of chylomicrons and low-density lipoproteins, which appears in plasma as two main isoforms: apoB48 (which is synthesised exclusively in the gut) and apoB100 (which is synthesised in the liver).

Molecular pathology
APOB mutations cause hypobetalipoproteinaemia, normotriglyceridemic hypobetalipoproteinaemia, and hypercholesterolaemia due to ligand-defective apoB.
Mentioned in ?
References in periodicals archive ?
LDL content was determined by protein quantification using the BioRad protein assay and assuming a formular weight of 540 kDa for apoB-100.
Synergistic inhibition of low-density lipoprotein oxidation by rutin, [gamma]-terpinene, and ascorbic acid
VLDL, IDL, LDL, and lipoprotein each contain one molecule of apoB-100.
Estimating LDL ApoB: infomania or clinical advance?
ApoB-100 is a target that has been of interest to the pharmaceutical industry for many years, but has been considered "undruggable" by traditional approaches.
Isis expands therapeutic potential of antisense inhibitor
At a dose of 50 mg/kg twice weekly, the murine apoB-100 antisense drug reduced total cholesterol and LDL-cholesterol by 87% and 93%, respectively.
Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
Furthermore, comparison of the samples analyzed in reduced and in native conditions clearly indicated that the apo(a) we detected in CSF samples was linked to apoB-100, as it was in the serum samples.
Lipoprotein(a) in the cerebrospinal fluid of neurological patients with blood-cerebrospinal fluid barrier dysfunction
19); apoB-100 protein content of the LDL fractions by the Lowry method; and total cholesterol, HDL cholesterol, and triglycerides by the enzymatic colorimetric method with commercial reagent sets (Roche Diagnostics).
Factors affecting S-homocysteinylation of LDL apoprotein B
Mipomersen, formerly ISIS 301012, is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol and a target that has proved to be undruggable using traditional, small-molecule approaches.
Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
This antibody is directed against a conformational epitope in the apolipoprotein B-100 (apoB-100) moiety of LDL that is generated as a consequence of substitution of at least 60 lysine residues of apoB-100 with aldehydes.
Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating Oxidized LDL
ISIS 301012 is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol and a target that has proved to be undruggable using traditional, small-molecule approaches.
Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
Notably, by ten weeks into the protocol-specified thirteen-week dosing period, all eight treated patients in the cohort had levels of apoB-100 that were at or below the lower limit of normal (<60 mg/dL), and four of the eight had undetectable levels of apoB-100 (<35 mg/dL).
New Data Presented at ACC Show ISIS 301012 Monotherapy Reduces apoB to Undetectable Levels and Reduces LDL-C 70%
33 apoA-I, mg/L 1310 [+ or -] 210 apoB-100, mg/L 780 [+ or -] 110 hs-CRP, mg/L 0.
Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity
ISIS 301012 is the Company's cholesterol-lowering drug targeting apoB-100.
Isis Pharmaceuticals Announces Its Participation at the Upcoming ACC 56th Annual Scientific Session in New Orleans and Its Live Analyst/Investor Webcast Presentation

Medical browser ?
Full browser ?